Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02834611 · ClinicalTrials.gov registry record · Phase 1
Ceramide NanoLiposome in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Keystone Nano.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02834611 is a Phase 1 study that has completed, run by Keystone Nano. The registered enrollment target is 14 participants.
The verdict
NCT02834611, a Phase 1 study, has completed, sponsored by Keystone Nano.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.
Interventions
- DRUG Ceramide NanoLiposome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02834611
The ClinicalTrials.gov registry entry for NCT02834611 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keystone Nano, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ceramide NanoLiposome is the first listed.
NCT02834611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02834611 about?
NCT02834611 is a clinical study titled "Ceramide NanoLiposome in Patients With Advanced Solid Tumors". This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.
What is the current status of trial NCT02834611?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2017-03-15. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT02834611?
The interventions under investigation include: Ceramide NanoLiposome (DRUG).
Who is sponsoring clinical trial NCT02834611?
This trial is sponsored by Keystone Nano, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.